HLS Therapeutics Inc.
HLS.TOTSXHealthcare● Active
$4.41
$-0.06(-1.34%)
Market Cap$137917017
P/E Ratio—
52W High$5.765
52W Low$0.001
HLS Therapeutics Inc. (HLS.TO) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · HLS.TO · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($12.65M) | ($19.66M) | ($27.53M) | ($23.60M) | ($13.12M) |
| Depreciation & Amort. | $22.20M | $22.72M | $31.94M | $34.40M | $30.26M |
| Stock-Based Comp. | $0.00M | $1.62M | ($0.54M) | $2.92M | $2.35M |
| Change in Working Capital | $4.82M | $1.14M | $5.04M | $1.55M | ($3.02M) |
| Net Cash from Operations | $16.02M | $8.00M | $15.79M | $16.94M | $16.43M |
| Investing Activities | |||||
| Capital Expenditure | ($0.21M) | ($0.01M) | ($0.19M) | ($10.15M) | ($4.51M) |
| Purchases of Investments | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Sales of Investments | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Cash from Investing | ($1.73M) | $11.73M | ($0.19M) | ($10.15M) | ($4.51M) |
| Financing Activities | |||||
| Common Stock Repurchased | ($1.83M) | ($0.60M) | ($1.55M) | ($1.00M) | ($0.05M) |
| Dividends Paid | $0.00M | $0.00M | ($2.40M) | ($4.96M) | ($5.12M) |
| Debt Issued / Repaid | ($18.07M) | ($21.57M) | ($9.46M) | ($0.44M) | ($11.14M) |
| Net Cash from Financing | ($20.52M) | ($23.36M) | ($14.64M) | ($6.86M) | ($11.40M) |
| Free Cash Flow | |||||
| Free Cash Flow | $15.81M | $7.99M | $15.60M | $6.79M | $11.92M |
| FCF Margin %(computed) | 27.99% | 14.11% | 24.73% | 11.05% | 19.86% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · M
Explore more HLS Therapeutics Inc. data
About HLS Therapeutics Inc. (HLS.TO) Cash Flow Statement
HLS Therapeutics Inc. generated operating cash flow of $0.02B and free cash flow of $0.02B for 2025 — a FCF margin of 27.99%. Capital expenditure was ($0.00B).
Frequently asked questions
HLS.TO · 4 questionsHLS Therapeutics Inc. generated free cash flow of $0.02B for 2025, up 97.9% year-over-year.
HLS.TO free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10